Johnson & Johnson (JNJ)’s Strong Second Quarter

Johnson & Johnson (NYSE:JNJ)Johnson & Johnson (NYSE:JNJ) today reported second-quarter results that had shareholders smiling. Top-line and bottom-line numbers reflected solid growth and beat analyst estimates. Shares were up around 1% in early trading.

By the numbers
Revenue for the second quarter came in at $17.9 billion. That reflects an 8.5% jump from the same quarter in 2012. The sales figure also beat analysts’ expectations of $17.7 billion.

Johnson & Johnson (NYSE:JNJ) reported net earnings for the quarter of $3.8 billion, or $1.33 per diluted share. Excluding special items, second quarter net earnings were $4.3 billion — a 17.7% year-over-year increase. The company reported non-GAAP earnings per diluted share of $1.48. That amount represents a 13.8% increase compared to the second quarter of last year. Analysts were anticipating non-GAAP earnings of $1.39 per share.

Special items during the quarter included $308 million in litigation expenses, $87 million in costs related to integration of Synthes, and $61 million related to the DePuy ASR Hip program. The total for these special items of $456 million was considerably less than the $2.2 billion reported for the second quarter of 2012.

Behind the numbers
Overall, international markets contributed more to growth than did U.S. markets. Johnson & Johnson (NYSE:JNJ) reported international sales growth of 9% compared to domestic sales growth of 8%.

Pharmaceuticals stood out as the fastest-growing division for Johnson & Johnson (NYSE:JNJ). Worldwide pharmaceutical sales jumped 11.7% year-over-year to $7 billion. The company’s biggest-selling drug, Remicade, generated sales of nearly $1.7 billion, up 9.8% compared to the second quarter of 2012.

Several other drugs in Johnson & Johnson (NYSE:JNJ)’s portfolio are growing strongly. Immunology drugs Symponi and Stelara grew sales by 40% and 49.6% year-over-year, respectively. Incivo experienced a sales jump of 68.6%. Sales for cancer drug Zytiga soared by over 70% compared to the second quarter of 2012.

Medical devices and diagnostics also performed well. Sales for the division totaled $7.2 billion, a 9.6% increase over the same quarter last year. This growth stemmed in large part from the acquisition of Synthes.

Consumer products lagged behind with sales of $3.7 billion — a 1.1% increase year-over-year. Over-the-counter drugs such as Tylenol and Motrin were solid contributors to these results, as were baby care and women’s health products.

Looking ahead
The future continues to look bright for Johnson & Johnson (NYSE:JNJ). The company increased its earnings guidance for full-year 2013 to $5.40-$5.47 per share excluding special items.

Prospects for sustained pharmaceuticals division growth, in particular, appear to be good. Johnson & Johnson (NYSE:JNJ) claims quite a few drugs building sales momentum, including Zytiga, Xarelto, and Incivo.

There are several solid pipeline candidates also. The Food and Drug Administration granted Breakthrough Therapy Designation to daratumumab in treating multiple myeloma. A New Drug Application, or NDA, was submitted earlier this year for ibrutinib as a treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma and as a second-line treatment for mantle cell lymphoma.

Add to all of this the fact that Johnson & Johnson (NYSE:JNJ) pays a dividend yield of 2.9% and has increased its dividend for 50 years in a row. The latest financial results simply underscore that Johnson & Johnson (NYSE:JNJ) has been and should continue to be a smart long-term investment.

The article Johnson & Johnson’s Strong Second Quarter originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

The 10 Largest Armies in the World: Who Should We Be Afraid Of?

Best Warren Buffett Quotes on Money You Need to Hear

The 10 Highest Suicide Rates by Profession

The 20 Most Underrated Movies of All Time

The 10 Fastest Growing Companies in America

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!